# A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

> **NCT00676715** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 220 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** Placebo
- **DRUG:** Ocrelizumab
- **DRUG:** Avonex

## Key facts

- **NCT ID:** NCT00676715
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07-17
- **Primary completion:** 2012-03-09
- **Final completion:** 2023-11-08
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2024-12-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00676715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00676715, "A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00676715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*